785 A phase I study of intralymphatic (IL) administration of ipilimumab (IPI) with intravenous nivolumab (NIVO) using the Sofusa® DoseConnect™ device in patients with advanced melanoma
Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A817-A817
10.1136/jitc-2022-sitc2022.0785